Light Adjustable Lens patient wearing the RxSight UV-protective glasses

RxSight™ 防紫外线眼镜:最佳做法和常见问题

Light Adjustable Lens™ (LAL™) 手术后,您将立即获得三副 RxSight 防紫外线眼镜,供您在不同环境下佩戴,对眼睛起到保护作用。这类眼镜为您提供了一层防紫外线 (UV) 光照的保护,以确保您的视力调整的稳定性。Light Adjustable Lens 上有一层名为 ActivShield 的特殊涂层,可提供额外的紫外线防护。

许多患者对这类眼镜都有疑问,比如“既然晶状体已经有紫外线防护功能,为什么我还需要眼镜?”以及“戴着眼镜我还能维持正常的日常活动吗?”在下文中,您可以找到这些问题和其他问题的答案,还可以深入了解使用 RxSight 防紫外线眼镜的更多最佳做法。

RxSight 防紫外线眼镜是如何工作的?

RxSight 防紫外线眼镜的所有镜架都是由透明的热塑性聚酰胺材料制成,具有良好的耐热性和抗紫外线性能。眼镜配备聚碳酸酯镜片,这是一种坚固、轻便的塑料材料,具有很强的抗冲击性。每副眼镜都具有相同程度的紫外线防护功能。在最后的锁定治疗之前,应在清醒时佩戴眼镜。

  • 有色眼镜:专为白天在户外佩戴而设计。
  • 透明眼镜:适用于室内一般活动。
  • 带有 1.50 D 阅读附加度数的透明眼镜:适用于室内近距离工作和阅读(如需要)。

佩戴 RxSight 防紫外线眼镜时,是否应避免任何特定活动?

虽然 RxSight 防紫外线眼镜能够提供必要的紫外线防护,但这类眼镜并不是安全护目镜,不应该用于滑雪、单板滑雪、游泳、浮潜或彩弹游戏等高冲击性活动。请注意您所从事的活动,因为在参加这些活动之前,您可能需要给眼睛更多的时间来恢复。在恢复这些活动之前,请咨询您的眼科手术护理团队。

虽然您必须在清醒时佩戴 RxSight 防紫外线眼镜,但睡觉和淋浴时可以摘下眼镜,除非有阳光直射。

RxSight 防紫外线眼镜有不同的尺寸吗?

有不同的尺寸可供选择,以确保佩戴合适。此外,RxSight 防紫外线眼镜还可以根据舒适度进行调整。侧臂可以调整,以确保眼镜牢固地贴合前额和脸颊上部。每副眼镜都配有挂绳,以增加安全性。如果您发现眼镜需要不同的尺寸或进行调整,请联系您的眼科手术护理团队,探讨可用的解决方案。

可以使用任何阻挡紫外线的眼镜吗?

不可以。RxSight 防紫外线眼镜经过严格测试,以确保它们能够为 Light Adjustable Lens 提供必要的保护。RxSight 无法保证其他阻挡紫外线的眼镜也能提供相同程度的保护。为确保最佳效果,请仅使用您的眼科手术护理团队提供的眼镜,并按照说明使用。

RxSight 防紫外线眼镜在您获得个性化视力的过程中起着至关重要的作用。按照指示佩戴眼镜,不仅能保护您的视力调整,还能最大限度地发挥 Light Adjustable Lens 的优势。

如需了解更多最佳做法和常见问题,请访问我们网站的常见问题页面

近期文章

白内障手术与干眼症:须知事项

固定型与可调节型晶状体设计:了解哪种设计更适合您

了解白内障手术:让您的视力从此更清晰

LAL patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

The Light Adjustable Lens provides optimized vision for patient satisfaction.2

Light Adjustable Lens patients saw nearly as well without glasses (UCDVA) as control patients did with glasses (BCDVA).

Since the Light Adjustable Lens is a monofocal lens, there is low risk of dysphotopsias caused by splitting light, leading to potentially enhanced vision and patient satisfaction.

LAL patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The Light Adjustable Lens offers LASIK-like accuracy in cataract surgery.2,3

92% of eyes (N = 391) achieved results within 0.50 D of target manifest refraction spherical equivalent (MRSE).

Patients are approximately two times more likely to achieve 20/20 vision or better without glasses at 6 months.

The study was a prospective, controlled, multicenter, 12-month study of 600 patients (ITT population) randomized to receive implantation with the RxSight LAL (N = 403) or a commercially available monofocal IOL (N = 197). Effectiveness analyses included 391 LAL patients and 193 control patients. Primary safety variables included best spectacle-corrected visual acuity (BSCVA) at 6 months and incidence of sight-threatening complications and adverse events. Primary effectiveness variables included percent reduction in manifest cylinder at 6 months, percent mean absolute reduction in MRSE at 6 months, and rotation of meridian of LAL at 6 months. Percent of eyes with an uncorrected visual acuity (UCVA) of 20/20 or better at six months post-operatively compared between the LAL treatment group and the monofocal control group was a secondary endpoint.

The Light Adjustable Lens corrects as low as 0.50 D of astigmatism, which is the lowest level approved to be treated.

The ability to treat 0.50 D of postoperative cylinder makes the Light Adjustable Lens the only IOL in the United States approved to correct this level of vision-altering astigmatism. Astigmatism of as little as 0.50 D can reduce visual acuity by one line, and the impact on dynamic, functional visual acuity and low-contrast acuity is even greater.1